Last updated on September 2018

An Observational Study of Herceptin SC Safety in Breast Cancer


Brief description of study

This is a phase IV, prospective, multicenter, observational study (regulatory post-marketing surveillance) in approximately 600 patients who are to receive Herceptin SC (trastuzumab, subcutaneous administration) per approved local labeling. Patients will be under observation according to standard of care in Korea.

Clinical Study Identifier: NCT02305628

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: ML29625 ...

Wonkwang University School of Medicine & Hospital
Jeonlabuk-do, Korea, Republic of
  Connect »